VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature

Clin Mol Hepatol. 2019 Jun;25(2):218-222. doi: 10.3350/cmh.2018.0017. Epub 2018 Sep 6.

Authors

Yu Jun Wong¹, Si Yuan Chew², John Chen Hsiang¹, Prem Harichander Thurairajah¹, Rahul Kumar¹, Eng Kiong Teo¹, Roshni Sadashiv Gokhale², Imran Bin Mohamed Noor², Jessica Tan¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
² Department of Respiratory Medicine and Critical Care, Changi General Hospital, Singapore, Singapore.

No abstract available

Publication types

Case Reports
Letter
Systematic Review

MeSH terms

Adult
Drug Combinations
Hepatitis C / drug therapy*
Humans
Lung Diseases, Interstitial / diagnosis*
Lung Diseases, Interstitial / etiology
Macrocyclic Compounds / adverse effects*
Macrocyclic Compounds / therapeutic use
Male
Middle Aged
Respiration, Artificial
Respiratory Function Tests
Ritonavir / adverse effects*
Ritonavir / therapeutic use
Sulfonamides / adverse effects*
Sulfonamides / therapeutic use
Tomography, X-Ray Computed
Uracil / adverse effects
Uracil / analogs & derivatives*
Uracil / therapeutic use

Substances

Drug Combinations
Macrocyclic Compounds
Sulfonamides
Viekira Pak
Uracil
Ritonavir